HIGHLIGHT ADVISORS

DAVID BLAUSTEIN

THE GALLEON GROUP,
NEW YORK, NY, USA

ERIK DE CLERCQ

KATHOLIEKE UNIVERSITEIT
LEUVEN, BELGIUM

RODERICK FLOWER

WILLIAM HARVEY RESEARCH
INSTITUTE, QMW, LONDON, UK

F. PETER GUENGERICH

VANDERBILT UNIVERSITY
NASHVILLE, TN, USA

FRANZ HEFTI

MERCK RESEARCH
LABORATORIES, SAN DIEGO,
CA, USA

JOAN HELLER BROWN

UNIVERSITY OF CALIFORNIA
SAN DIEGO, CA, USA

MADS KROGSGAARD THOMSEN

NOVO NORDISK, BAGSVAERD,
DENMARK

HUGO KUBINYI

UNIVERSITY OF HEIDELBERG,
GERMANY

JULIO LICINIO

UNIVERSITY OF CALIFORNIA
LOS ANGELES, CA, USA

CHRISTOPHER LIPINSKI

PFIZER GLOBAL RESEARCH
AND DEVELOPMENT, GROTON,
CT, USA

LESLIE MEYER-LEON

IP LEGAL STRATEGIES GROUP,
OSTERVILLE, MA, USA

TOMI SAWYER

ARIAD PHARMACEUTICALS,
CAMBRIDGE, MA, USA

GEORGE SCHLICH

MATHYS & SQUIRE,
LONDON, UK

JANET WOODCOCK

CENTER FOR DRUG
EVALUATION AND RESEARCH,
WASHINGTON, MD, USA

NEURODEGENERATIVE DISEASE

The early results of misfolding

It has long been known that many serious diseases are associated with problems in protein folding. Insoluble clusters of misfolded proteins are a common pathological feature of conditions such as Alzheimer's disease and encephalopathies, but the connection between these disease-linked aggregates and the detrimental effects on health is still unclear. Now, two studies published in *Nature* provide evidence that early, misfolded intermediates on the path to forming these aggregates might be responsible for at least part of the damage.

Newly synthesized proteins adopt characteristic three-dimensional structures on the basis of their individual amino-acid sequences, but a common feature of all protein folding is that hydrophobic residues tend to be hidden within the body of the folded molecule. When folding goes wrong, and hydrophobic residues are exposed on the surface of proteins, the misfolded proteins clump together to form aggregates. Once of a certain size, these are deposited within or outside cells as insoluble deposits, the most well known being the amyloid- β (A β) plaques seen in Alzheimer's disease.

Investigating the toxicity of intermediates in the path from simple A β monomers to insoluble A β plaques, Walsh *et al.* found that soluble A β oligomers, formed from two or three associated A β molecules, were able to interfere with synaptic plasticity. When injected into rat brains, A β oligomers derived from cultured cells expressing

mutated amyloid- β precursor protein (APP) were able to inhibit hippocampal long-term potentiation. This ability to disrupt processes thought to be crucial to memory formation indicates that A β oligomers might be the leading culprits in inhibiting neuronal function in Alzheimer's disease. Furthermore, the extent of the dementia experienced by Alzheimer's patients has previously been found to correlate well with their levels of soluble A β , but not with the density of amyloid plaques.

The second paper, by Bucciantini *et al.*, similarly finds that a species formed early during the process of protein aggregation is damaging to cell function. In this case, however, the misfolded protein is the amino-terminal domain of the bacterial regulatory HypF protein (HypF-N), one not normally associated with any disease state. The authors have previously shown that under suitable conditions, amyloid fibrils can be induced to form from proteins not thought to be linked to any disease, and here, they study the cytotoxicity of intermediates on the route to forming the HypF-N fibrils. Their finding that aggregates and protofibrils of HypF-N are deadly to cultured mouse fibroblasts,

but that mature HypF-N fibrils are not, leads them to conclude that minute amounts of early aggregates of proteins might impair cellular function, without insoluble deposits being present. The fact that a protein totally unassociated with neurological disease can cause these effects raises the possibility that the spontaneous development of early aggregates of proteins that are not under suspicion at present might underlie the development of various diseases.

Together, these demonstrations of aggregate pathogenicity indicate that an understanding of the mechanisms that underlie aggregate formation, and of why the cellular control mechanisms that normally prevent it break down, might be just as important for future therapeutic approaches as an understanding of the biology of individual disease-associated proteins.

Adam Smith

References and links

ORIGINAL RESEARCH PAPERS Bucciantini, M. *et al.* Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. *Nature* **416**, 507–511 (2002) | Walsh, D. M. *et al.* Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation *in vivo*. *Nature* **416**, 535–539 (2002)